Aptose Biosciences (GB:0UI8)

Aptose Biosciences (0UI8) Stock Price & Analysis


0UI8 Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$3.05 - C$3.05
Previous CloseC$3.05
Average Volume (3M)N/A
Market Cap
Enterprise ValueC$6.64M
Total Cash (Recent Filing)$55.39M
Total Debt (Recent Filing)$271.00K
Price to Earnings (P/E)-5.2
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding92,367,275
10 Day Avg. Volume353
30 Day Avg. VolumeN/A
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.21
Price Target Upside243.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3




What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$3.05 and its highest was C$3.05 in the past 12 months.
    What is Aptose Biosciences’s market cap?
    Currently, no data Available
    When is Aptose Biosciences’s upcoming earnings report date?
    Aptose Biosciences’s upcoming earnings report date is May 09, 2023 which is in 42 days.
      How were Aptose Biosciences’s earnings last quarter?
      Aptose Biosciences released its earnings results on Mar 23, 2023. The company reported -C$0.15 earnings per share for the quarter, missing the consensus estimate of -C$0.147 by -C$0.003.
        Is Aptose Biosciences overvalued?
        According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aptose Biosciences pay dividends?
          Aptose Biosciences does not currently pay dividends.
          What is Aptose Biosciences’s EPS estimate?
          Aptose Biosciences’s EPS estimate is -C$0.16.
            How many shares outstanding does Aptose Biosciences have?
            Aptose Biosciences has 93,005,280 shares outstanding.
              What happened to Aptose Biosciences’s price movement after its last earnings report?
              Aptose Biosciences reported an EPS of -C$0.15 in its last earnings report, missing expectations of -C$0.147. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Aptose Biosciences?
                Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at 1M.


                  Aptose Biosciences Stock Smart Score

                  The Aptose Biosciences Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aptose Biosciences

                  Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  BriaCell Therapeutics
                  Portage Biotech Inc
                  Fusion Pharmaceuticals
                  Eupraxia Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis